Home > Newsletters > Generic Line > Fed Circuit: ‘Safe Harbor’ Provision Is Broad: Amphastar, Momenta Dispute
Aug. 15, 2012 | Vol. 29 No. 16
Fed Circuit: ‘Safe Harbor’ Provision Is Broad: Amphastar, Momenta Dispute
A 2–1 final federal appeals court decision that lifts an injunction barring Watson Pharmaceuticals and Amphastar from selling a generic version of Sanofi’s blockbuster blood-thinner Lovenox hinged on an expansive interpretation of Hatch-Waxman’s “safe harbor” provision — a move that could have wide-ranging implications for all patent holders, warns Momenta Pharmaceuticals, which lost its appeal.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.